Premium
A cost‐effectiveness analysis of modafinil therapy for psychostimulant dependence
Author(s) -
SHEARER JAMES,
SHANAHAN MARIAN,
DARKE SHANE,
RODGERS CRAIG,
VAN BEEK INGRID,
MCKETIN REBECCA,
MATTICK RICHARD P.
Publication year - 2010
Publication title -
drug and alcohol review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.018
H-Index - 74
eISSN - 1465-3362
pISSN - 0959-5236
DOI - 10.1111/j.1465-3362.2009.00148.x
Subject(s) - modafinil , psychology , psychiatry , medicine , psychotherapist
and Aims. To examine the cost‐effectiveness of modafinil (200 mg daily) plus counselling compared with placebo for the treatment of psychostimulant dependence. Design and Methods. Cost and outcome data were collected alongside two randomised controlled trials of modafinil 200 mg daily over 10 weeks for methamphetamine ( n = 74) and cocaine dependence ( n = 8), respectively. Incremental cost‐effectiveness ratios representing the additional costs to achieve a given outcome were calculated for both the change in the number of stimulant‐free days and quality‐adjusted life years 12 weeks post‐treatment. Results. The incremental cost‐effectiveness ratio indicated that it would cost an additional $AUD79 to achieve an extra stimulant‐free day with modafinil compared with placebo. This result was not statistically significant, but appeared to be a robust estimate after sensitivity analysis. Counselling, whether received within program or from other services, improved the cost‐effectiveness of modafinil relative to placebo. Discussion and Conclusions. Strategies to improve the uptake of counselling are recommended as cost‐effective. [Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, Mattick RP. A cost‐effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev 2010]